Oliver N Refugio1, Mabel M Kimble2, Cara L Silva3, James E Lykens4, Christian Bannister3, Jeffrey D Klausner2. 1. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA. 2. Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA. 3. Youth Tech Health (YTH), San Francisco, CA. 4. San Francisco State University, Center for Research and Education on Gender and Sexuality, San Francisco, CA.
Abstract
BACKGROUND: In the United States, young men who have sex with men (YMSM) of color represent a high number of new HIV diagnoses annually. HIV pre-exposure prophylaxis (PrEP) is effective and acceptable to YMSM of color; yet, PrEP uptake is low in those communities because of barriers including stigma, cost, adherence concerns, and medical distrust. A telehealth-based approach to PrEP initiation may be a solution to those barriers. This pilot study investigates one such intervention called PrEPTECH. METHODS: We enrolled 25 HIV-uninfected YMSM, aged 18-25 years, from the San Francisco Bay Area into a 180-day longitudinal study between November 2016 and May 2017. Participants received cost-free PrEP services through telehealth [eg, telemedicine visits, home delivery of Truvada, and sexually transmitted infection testing kits], except for 2 laboratory visits. Online survey assessments querying PrEPTECH features and experiences were administered to participants at 90 and 180 days. RESULTS: Eighty-four percent of participants were YMSM of color. Among the 21 who completed the study, 11 of the 16 who wanted to continue PrEP were transitioned to sustainable PrEP providers. At least 75% felt that PrEPTECH was confidential, fast, convenient, and easy to use. Less than 15% personally experienced PrEP stigma during the study. The median time to PrEP initiation was 46 days. Sexually transmitted infection positivity was 20% and 19% at baseline and 90 days, respectively. No HIV infections were detected. CONCLUSIONS: Telehealth programs such as PrEPTECH increase PrEP access for YMSM of color by eliminating barriers inherent in traditional clinic-based models.
BACKGROUND: In the United States, youngmen who have sex with men (YMSM) of color represent a high number of new HIV diagnoses annually. HIV pre-exposure prophylaxis (PrEP) is effective and acceptable to YMSM of color; yet, PrEP uptake is low in those communities because of barriers including stigma, cost, adherence concerns, and medical distrust. A telehealth-based approach to PrEP initiation may be a solution to those barriers. This pilot study investigates one such intervention called PrEPTECH. METHODS: We enrolled 25 HIV-uninfected YMSM, aged 18-25 years, from the San Francisco Bay Area into a 180-day longitudinal study between November 2016 and May 2017. Participants received cost-free PrEP services through telehealth [eg, telemedicine visits, home delivery of Truvada, and sexually transmitted infection testing kits], except for 2 laboratory visits. Online survey assessments querying PrEPTECH features and experiences were administered to participants at 90 and 180 days. RESULTS: Eighty-four percent of participants were YMSM of color. Among the 21 who completed the study, 11 of the 16 who wanted to continue PrEP were transitioned to sustainable PrEP providers. At least 75% felt that PrEPTECH was confidential, fast, convenient, and easy to use. Less than 15% personally experienced PrEP stigma during the study. The median time to PrEP initiation was 46 days. Sexually transmitted infection positivity was 20% and 19% at baseline and 90 days, respectively. No HIV infections were detected. CONCLUSIONS: Telehealth programs such as PrEPTECH increase PrEP access for YMSM of color by eliminating barriers inherent in traditional clinic-based models.
Authors: Sarah J Marks; Roland C Merchant; Melissa A Clark; Tao Liu; Joshua G Rosenberger; Jose Bauermeister; Kenneth H Mayer Journal: AIDS Patient Care STDS Date: 2017-11 Impact factor: 5.078
Authors: Sybil G Hosek; Bret Rudy; Raphael Landovitz; Bill Kapogiannis; George Siberry; Brandy Rutledge; Nancy Liu; Jennifer Brothers; Kathleen Mulligan; Gregory Zimet; Michelle Lally; Kenneth H Mayer; Peter Anderson; Jennifer Kiser; James F Rooney; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Javeed Siddiqui; Thomas Herchline; Summerpal Kahlon; Kay J Moyer; John D Scott; Brian R Wood; Jeremy Young Journal: Clin Infect Dis Date: 2017-02-01 Impact factor: 9.079
Authors: David W Pantalone; Kimberly M Nelson; Abigail W Batchelder; Christopher Chiu; Hamish A Gunn; Keith J Horvath Journal: J Sex Res Date: 2020-02-20
Authors: Eric K Layland; Joseph A Carter; Nicholas S Perry; Jorge Cienfuegos-Szalay; Kimberly M Nelson; Courtney Peasant Bonner; H Jonathon Rendina Journal: Transl Behav Med Date: 2020-10-12 Impact factor: 3.046
Authors: A Lina Rosengren; Corina Lelutiu-Weinberger; E Wilbur Woodhouse; Priyadharshiny Sandanapitchai; Lisa B Hightow-Weidman Journal: AIDS Behav Date: 2021-01-02
Authors: Christine M Khosropour; Kandis V Backus; Arianna R Means; Laura Beauchamps; Kendra Johnson; Matthew R Golden; Leandro Mena Journal: AIDS Patient Care STDS Date: 2020-01 Impact factor: 5.078
Authors: Jayleen K L Gunn; Cherie Rooks-Peck; Megan E Wichser; Christa Denard; Donna Hubbard McCree; William L Jeffries; Julia B DeLuca; Leslie W Ross; Adrienne Herron; Terrika Barham; Stephen A Flores; Darrel H Higa Journal: AIDS Behav Date: 2021-07-14